VJHemOnc Podcast
The CLL Sessions: highlights from EHA and ICML 2021
Jul 27, 2021
Experts Paolo Ghia, Susan O'Brien, Lydia Scarfò, and Othman Al-Sawaf review exciting updates in chronic lymphocytic leukemia (CLL) from EHA and ICML 2021. They discuss key clinical trials, second-generation BTKs, fixed-duration therapy, depth of response, stopping treatment, retreatment potential, progression-free survival, VTK inhibitors, akylobrutinib vs. britinib, and different CLL treatment regimens.
36:42
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- iBrutinib is an effective treatment for chronic lymphocytic leukemia (CLL), particularly for unmutated patients.
- Venetoclax in combination with chemoimmunotherapy shows superior progression-free survival (PFS) rates compared to chlorambucil, especially for unmutated CLL patients.
Deep dives
Update on iBrutinib for CLL
The seven-year update on the iBrutinib trial showed no median progression free survival, with 61% progression free survival at six and a half years. The treatment showed durable remissions, even in the absence of complete responses or undetectable minimal residual disease (MRD). Remarkably, there was no difference in outcome between patients with mutated and unmutated CLL. These results suggest that iBrutinib is an effective treatment, particularly for unmutated patients.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
